Worldwide utilization of implantable cardioverter/defibrillators now and in the future

Cardiac Electrophysiology Review
K Seidl, J Senges

Abstract

Despite the demonstrated efficacy of implantable cardioverter defibrillators (ICDs) in reducing sudden and total mortality in selected patients, their implantation rates vary greatly between countries. In the United States, implantation rate is 228 implants per million inhabitants compared to only 45 implants per million in Western Europe. The differences in the ICD use may be explained by following factors: manner in which sudden cardiac death is perceived by politicians and physicians (sudden cardiac death is perceived as a "nice way of dying"); differences in indications; physicians' information; prevalence of coronary artery disease; sudden cardiac death survival rates; perceived reliability of alternative treatment (namely antiarrhythmics including amiodarone); economic backgrounds; and health care politics. Furthermore, the cost of this treatment strategy must be considered. This issue has been raised because generalization of ICD use in patients matching clinical characteristics of patients enrolled in the primary prevention trials may represent a significant economic burden to be added to the already overloaded health care system. This low acceptance may not be entirely related to budget constraint but also to the perce...Continue Reading

Citations

Jun 9, 2006·Progress in Cardiovascular Nursing·Genevieve SmithBindu Viswanathan
Jan 20, 2007·International Journal of Technology Assessment in Health Care·Jackie BryantAndrew Clegg
Oct 3, 2009·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Janet M McCombDavid Cunningham
Apr 20, 2010·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Roberto F E PedrettiUNKNOWN ALPHA Study Group Investigators
Aug 23, 2006·Pacing and Clinical Electrophysiology : PACE·Dwarakraj SoundarrajKrit Jongnarangsin
Jan 28, 2009·Pacing and Clinical Electrophysiology : PACE·Susanne S PedersenDominic A M J Theuns
Mar 18, 2011·Pacing and Clinical Electrophysiology : PACE·Sek Y ChairSamuel F Sears
Apr 22, 2006·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Margret LeosdottirDavid O Arnar
May 26, 2006·BMC Cardiovascular Disorders·Margret LeosdottirDavid O Arnar
Jan 28, 2009·Pacing and Clinical Electrophysiology : PACE·Susanne S PedersenKrista C Van Den Broek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.